Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
TTHI's Cash to Debt is ranked higher than
92% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. TTHI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
TTHI' s 10-Year Cash to Debt Range
Min: 4.13  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
TTHI's Interest Coverage is ranked higher than
85% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. TTHI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
TTHI' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 1
Z-Score: 0.12
M-Score: -3.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -107.59
TTHI's ROE (%) is ranked lower than
82% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. TTHI: -107.59 )
Ranked among companies with meaningful ROE (%) only.
TTHI' s 10-Year ROE (%) Range
Min: -66.78  Med: -37.91 Max: 0.07
Current: -107.59
-66.78
0.07
ROA (%) -89.57
TTHI's ROA (%) is ranked lower than
84% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. TTHI: -89.57 )
Ranked among companies with meaningful ROA (%) only.
TTHI' s 10-Year ROA (%) Range
Min: -55.68  Med: -30.32 Max: 0.06
Current: -89.57
-55.68
0.06
ROC (Joel Greenblatt) (%) -28463.94
TTHI's ROC (Joel Greenblatt) (%) is ranked lower than
94% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. TTHI: -28463.94 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TTHI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -13626.3  Med: -2397.95 Max: -539.43
Current: -28463.94
-13626.3
-539.43
Revenue Growth (3Y)(%) -100.00
TTHI's Revenue Growth (3Y)(%) is ranked lower than
94% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. TTHI: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TTHI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -100.00 Max: 91.3
Current: -100
0
91.3
EBITDA Growth (3Y)(%) 80.90
TTHI's EBITDA Growth (3Y)(%) is ranked higher than
96% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. TTHI: 80.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TTHI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -5.80 Max: 80.9
Current: 80.9
0
80.9
EPS Growth (3Y)(%) 42.30
TTHI's EPS Growth (3Y)(%) is ranked higher than
89% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. TTHI: 42.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TTHI' s 10-Year EPS Growth (3Y)(%) Range
Min: -100  Med: -10.25 Max: 51.8
Current: 42.3
-100
51.8
» TTHI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

TTHI Guru Trades in Q2 2014

Jim Simons 131,300 sh (+0.15%)
» More
Q3 2014

TTHI Guru Trades in Q3 2014

Jim Simons 149,700 sh (+14.01%)
» More
Q4 2014

TTHI Guru Trades in Q4 2014

Jim Simons 175,400 sh (+17.17%)
» More
Q1 2015

TTHI Guru Trades in Q1 2015

Jim Simons 190,700 sh (+8.72%)
» More
» Details

Insider Trades

Latest Guru Trades with TTHI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.16
TTHI's P/B is ranked higher than
78% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. TTHI: 2.16 )
Ranked among companies with meaningful P/B only.
TTHI' s 10-Year P/B Range
Min: 0.85  Med: 2.95 Max: 7.53
Current: 2.16
0.85
7.53
Current Ratio 10.99
TTHI's Current Ratio is ranked higher than
77% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. TTHI: 10.99 )
Ranked among companies with meaningful Current Ratio only.
TTHI' s 10-Year Current Ratio Range
Min: 2.24  Med: 9.79 Max: 30.83
Current: 10.99
2.24
30.83
Quick Ratio 10.99
TTHI's Quick Ratio is ranked higher than
77% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. TTHI: 10.99 )
Ranked among companies with meaningful Quick Ratio only.
TTHI' s 10-Year Quick Ratio Range
Min: 1.66  Med: 9.79 Max: 30.83
Current: 10.99
1.66
30.83

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.73
TTHI's Price/Net Cash is ranked higher than
87% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. TTHI: 2.73 )
Ranked among companies with meaningful Price/Net Cash only.
TTHI' s 10-Year Price/Net Cash Range
Min: 2.13  Med: 6.52 Max: 64
Current: 2.73
2.13
64
Price/Net Current Asset Value 2.60
TTHI's Price/Net Current Asset Value is ranked higher than
87% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. TTHI: 2.60 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
TTHI' s 10-Year Price/Net Current Asset Value Range
Min: 1.54  Med: 6.08 Max: 40
Current: 2.6
1.54
40
Price/Tangible Book 2.60
TTHI's Price/Tangible Book is ranked higher than
77% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. TTHI: 2.60 )
Ranked among companies with meaningful Price/Tangible Book only.
TTHI' s 10-Year Price/Tangible Book Range
Min: 1.52  Med: 5.28 Max: 38.25
Current: 2.6
1.52
38.25
Earnings Yield (Greenblatt) (%) -79.29
TTHI's Earnings Yield (Greenblatt) (%) is ranked lower than
94% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. TTHI: -79.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TTHI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -121.5  Med: 0.00 Max: 0
Current: -79.29
-121.5
0

Analyst Estimate

Jun15 Jun16 Jun17 Jun18
EPS($) -0.99 -0.27 -0.17 -0.13
EPS without NRI($) -0.99 -0.27 -0.17 -0.13

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:TTH.Canada, RFYA.Germany,
Transition Therapeutics Inc was incorporated on July 6, 1998 as 'Transition Therapeutics and Diagnostics Inc.' The Corporation filed articles of amendment on October 12, 2000 and on October 19, 2000 to create a class of non-voting shares (the 'Class B Shares') and to amend certain attributes of its Common Shares. On November 2, 2000, the Corporation filed articles of amendment to delete its private company restrictions. On December 14, 2000, the Corporation filed articles of amendment to change its name to 'Transition Therapeutics Inc.' The Company is a product-focused biopharmaceutical company developing novel therapeutics for disease indications with markets. The Company's technologies are focused on the treatment of Alzheimer's disease and diabetes. The Corporation operates in one business segment; that is the research and development of therapeutic agents. Its technologies in development include ELND005 (AZD-103) for the treatment of Alzheimer's disease; TT-301 and TT-302 which may have a therapeutic effect on diseases including arthritis, Alzheimer's disease, traumatic brain injury, intracerebral haemorrhage, and others, and TT401/402 for the treatment of diabetes. On July 15, 2011, the Company announced that ELND005 Phase 2 clinical trial data would be presented at the International Conference of Alzheimer's Disease (ICAD) meeting on July 18, 2011. Elan and Transition intend to share further detail regarding the Phase 2 data in a peer-reviewed publication.
» More Articles for TTHI

Headlines

Articles On GuruFocus.com
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 

More From Other Websites
Transition Therapeutics Tanks on Alzheimer's Disease Data - Analyst Blog Jun 25 2015
Wednesday's Mid-Day Movers: Fitbit, Transition Therapeutics Losing Big; Celator Pharma, MeetMe Up Jun 24 2015
BUZZ-U.S. STOCKS ON THE MOVE-Transition Therapeutics, Celator, Meetme Jun 24 2015
Transition Therapeutics Announces Results of Clinical Study of ELND005 in Agitation and Aggression... Jun 24 2015
Transition Therapeutics Announces Results of Clinical Study of ELND005 in Agitation and Aggression... Jun 24 2015
Transition Therapeutics Appoints Carl Damiani as President Jun 16 2015
Transition Therapeutics Appoints Carl Damiani as President Jun 16 2015
Transition Therapeutics to Present at the Jefferies 2015 Healthcare Conference May 26 2015
Transition Therapeutics to Present at the Jefferies 2015 Healthcare Conference May 26 2015
Transition Therapeutics posts 3Q loss May 12 2015
Transition Therapeutics posts 3Q loss May 12 2015
Transition Therapeutics Announces Third Quarter Fiscal 2015 Financial Results May 12 2015
Transition Therapeutics Announces Third Quarter Fiscal 2015 Financial Results May 12 2015
Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2015 Financial Results on... May 07 2015
Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2015 Financial Results on... May 07 2015
Transition Therapeutics In-Licenses Phase 2 Drug Candidate from Lilly May 06 2015
Transition Therapeutics Announces Results from Phase 1 AME & Renal Clearance Clinical Studies of... Mar 26 2015
Transition Therapeutics Announces Results from Phase 1 AME & Renal Clearance Clinical Studies of... Mar 26 2015
Transition Therapeutics Announces Enrolment Completion of ELND005 Phase 2 Clinical Study in... Mar 02 2015
Transition Therapeutics Announces Enrolment Completion of ELND005 Phase 2 Clinical Study in... Mar 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK